Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

Core Insights - Revolution Medicines has initiated its first-in-human clinical trial for RMC-5127, a selective inhibitor targeting the RAS G12V mutation, which is prevalent in various cancers [1][2][3] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [4] - The company's R&D pipeline includes multiple RAS(ON) inhibitors, with RMC-5127 being the fifth disclosed mutant-selective inhibitor and the fourth in clinical development [3][4] Clinical Trial Details - The trial, named RMC-5127-001, is an open-label study assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of RMC-5127 as both a monotherapy and in combination settings [2] - It will enroll patients with RAS G12V–mutated solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non–small cell lung cancer (NSCLC), who have either progressed on or are intolerant to prior standard therapies [2] Market Opportunity - RAS G12V is the second most common RAS mutation, with approximately 48,000 new cases diagnosed annually in the U.S., primarily among patients with PDAC, CRC, or NSCLC [3]